We are currently enrolling treatment studies on Tourette Syndrome.  We frequently develop new research studies and have created a Volunteer Research Registry to keep people updated on studies for which they might be eligible. If you would like to be contacted about new research studies, please complete the Volunteer Research Registry.

If you are interested in learning more about our studies and whether you might be eligible to participate in one, please contact us at:

1-877-501-TICS
tics@partners.org

Treatment studies

Modified CBIT for Children with Tic Disorder, Co-occurring ADHD, and Psychosocial Impairment

PI’s: Dr. Erica Greenberg, M.D.

Study contact:

• Valerie Braddick
• vbraddick@mgh.harvard.edu
• 617-643-4387

Purpose of the study: If you have a child aged 10-17 who is bothered by tics and ADHD symptoms, we may be able to help. Massachusetts General Hospital is conducting a no-cost clinical trial with children and adolescents (ages 10 to 17 years) who are bothered by their tics and who also are suffering from ADHD. Those qualified will receive a diagnostic evaluation and either a standard or modified course of CBIT (comprehensive behavioral intervention for tics) at no cost.

Eligibility: Children and adolescents (ages 10 to 17 years) who are bothered by their tics and who also are suffering from ADHD.

Length of the study: 6 months

Visit type: Therapy & diagnostic evaluation

Payment: Parking costs are reimbursed.

A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents (Phase 2/3)

PI: Daniel Geller, M.D.

Study contact:

• Hannah Smilansky
• hsmilansky@mgh.harvard.edu
• 617-726-5527

Purpose of the study: We are investigating deutetrabenazine (TEV-50717) as a possible treatment option for Tourette syndrome (TS) in children and adolescents. Specifically, we are looking at the efficacy of TEV-50717 for the reduction of motor and phonic tics associated with TS. Participants will be randomized to receive either TEV-50717 or placebo for the duration of the study. After completing the randomized study, participants may have the option to enroll in the open-label extension study. If your child is 6-16 years old and is bothered by tics associated with TS, they may be eligible to participate.

Eligibility: Children and adolescents, 6 through 16 years of age, with Tourette syndrome

Length of the study: The overall treatment period is 12 weeks long, including a titration period of 7 weeks, a maintenance period of 5 weeks, and a 1 week washout period.

Visit type: Participation includes clinician-administered measures, safety assessments (such as blood draws, ECGs, and vital signs), and questionnaires for you and your child to complete. Your child would receive the study drug or placebo during the visit, and take it at home under the supervision of a parent or legal guardian.

Payment: You or your child will be paid up to $525 for your participation and will receive reimbursement for parking.

T-Force Platinum – Nationwide Research Study for Children and Adolescents with Tourette Syndrome

PI: Dr. Daniel Geller, M.D

Study Contact:

• Hannah Smilansky
• hsmilansky@mgh.harvard.edu
• 617-726-5527

Purpose of the study: A clinical research study for children and adolescents with Tourette syndrome. Neurocrine Biosciences invites boys and girls aged 6 to 17 who have a diagnosis of Tourette syndrome to see if they may qualify for the T-Force Platinum Study. The primary purpose of this research study is to determine the safety and effectiveness of an investigational medication, that is not an antipsychotic medication, in pediatric patients with Tourette syndrome.

Each child will be evaluated to determine his or her eligibility to participate in the research study. All who qualify will receive either the investigational medication or placebo (inactive substance), study-related medical exams and study-related laboratory tests at no cost. Compensation for time and travel may also be available.

If you have friends or family who are also affected by Tourette’s, we encourage you to pass this information along. We encourage you to talk to your child’s doctor or contact the participating physician in your area.

Eligibility: Boys and girls aged 6 to 17 who have a diagnosis of Tourette syndrome